NCT01398098

Brief Summary

Ultra-sound study to assess changes in intragastric volume after bowel preparation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Oct 2011

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 13, 2011

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 20, 2011

Completed
2 months until next milestone

Study Start

First participant enrolled

October 1, 2011

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2012

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2012

Completed
Last Updated

November 29, 2012

Status Verified

November 1, 2012

Enrollment Period

7 months

First QC Date

July 13, 2011

Last Update Submit

November 28, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percentage of patients with a residual antral volume lower than 20 mL

    after 2nd treatment regimen intake

Secondary Outcomes (3)

  • Adverse events

    After drug intake

  • Acceptability of COLOKIT®.

    After drug intake

  • Colonoscopy results

    After colonoscopy.

Study Arms (1)

COLOKIT®

EXPERIMENTAL
Drug: Sodium phosphate

Interventions

32 tablets

COLOKIT®

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject who signed an informed consent to participate in the trial.
  • Subject affiliated with Social Security
  • Men and women aged 18 to 75 years.
  • Subject with an indication of scheduled outpatient colonoscopy.
  • colonoscopy performed within six hours after the second sequence COLOKIT®.
  • Subject able to swallow tablets.

You may not qualify if:

  • Women pregnant or likely to be (without contraception) or nursing.
  • Subject having any of the following diseases or conditions:
  • allergy or hypersensitivity to the product tested or any of its excipients,
  • nausea, vomiting or abdominal pain,
  • clinically significant renal failure,
  • primary hyperparathyroidism associated with hypercalcemia,
  • congestive heart failure,
  • ascites,
  • a known or suspected bowel obstruction,
  • megacolon (congenital or acquired)
  • intestinal perforation,
  • ileus,
  • an inflammatory disease or suspected inflammatory bowel disease,
  • swallowing disorders,
  • known digestive motor disorders (gastroparesis, scleroderma, mega-esophagus),
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cochin Hospital

Paris, 75014, France

Location

Related Publications (1)

  • Coriat R, Polin V, Oudjit A, Henri F, Dhooge M, Leblanc S, Delchambre C, Esch A, Tabouret T, Barret M, Prat F, Chaussade S. Gastric emptying evaluation by ultrasound prior colonoscopy: an easy tool following bowel preparation. World J Gastroenterol. 2014 Oct 7;20(37):13591-8. doi: 10.3748/wjg.v20.i37.13591.

MeSH Terms

Interventions

sodium phosphate

Study Officials

  • Stanislas CHAUSSADE, Professor

    Cochin Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 13, 2011

First Posted

July 20, 2011

Study Start

October 1, 2011

Primary Completion

May 1, 2012

Study Completion

September 1, 2012

Last Updated

November 29, 2012

Record last verified: 2012-11

Locations